Health Catalyst Stock Price, News & Analysis

Health Catalyst (Nasdaq: HCAT) reported strong Q2 2021 financial results, exceeding revenue and Adjusted EBITDA guidance. The company achieved a positive Adjusted EBITDA of $1.7 million, marking a significant milestone since its inception. Technology revenue rose 39% to $35.5 million, while total revenue increased 38% to $59.6 million compared to Q2 2020. The recent acquisition of Twistle, effective July 1, 2021, is expected to enhance its Population Health analytics offerings. However, the company reported a net loss of $35.8 million, a 32% increase from the previous year.

Health Catalyst, a top provider of data and analytics for healthcare, announced participation in the 41st Annual Canaccord Genuity Growth Stock Conference. CFO Bryan Hunt and SVP Adam Brown will present in a fireside chat on August 11, 2021, at 2:00 p.m. ET. The company is dedicated to using data for healthcare improvements, utilizing a cloud-based platform that processes over 100 million patient records.

Health Catalyst aims for a future where all healthcare decisions are informed by data, enhancing clinical, financial, and operational outcomes.

Health Catalyst (Nasdaq: HCAT) will release its 2021 second quarter operating results on August 5, 2021, after market close. The company will host a conference call at 5 p.m. E.T. that day to discuss the results. Participants can join by calling 1-800-708-4539 (U.S.) or 1-847-619-6396 (international) using the code 50199342. A live audio webcast will be available, with a replay accessible for 90 days afterward. Health Catalyst is known for data and analytics technology that improves clinical, financial, and operational aspects for healthcare organizations.

Health Catalyst (Nasdaq: HCAT) has launched Value Optimizer, a new solution aimed at enhancing value-based care (VBC) performance for healthcare organizations. This technology addresses limitations in traditional population health tools by providing comprehensive data and insights necessary for effective VBC strategy management. Key features include a quantified view of financial opportunities, continually updated data, transparent methodologies for benchmarking, and expert guidance for maximizing performance. This solution aims to help healthcare providers lower costs while maintaining the quality of care.

Health Enterprise Partners (HEP) announced five realizations of portfolio companies and a new investment in Kno2, marking its tenth platform investment from HEP III. HEP focuses on founder-financed businesses, having previously invested in Twistle, which enhances patient engagement in healthcare. Health Catalyst (NASDAQ: HCAT) disclosed its acquisition of Twistle, enhancing its data and analytics services. Privia Health (NASDAQ: PRVA) completed a successful IPO, raising approximately $131.7 million. HEP's new investment in Kno2 will support interoperability in healthcare, aiming for better patient information exchange.

Health Catalyst (Nasdaq: HCAT) announced a definitive agreement to acquire Twistle, a patient engagement SaaS company based in Albuquerque, New Mexico. The acquisition aims to enhance patient-centered communication and improve healthcare outcomes by integrating Twistle’s workflow technology with Health Catalyst's data platform, DOS™. The transaction is expected to close in early Q3 2021 and will be funded through a mix of stock and cash. The synergy aims to drive better care and reduce costs, aligning with Health Catalyst's mission to leverage data for healthcare improvements.

Health Catalyst, a key player in data and analytics for healthcare, announced participation in the 41st Annual William Blair Growth Stock Conference on June 2, 2021, at 5:40 p.m. ET. CEO Dan Burton and SVP Adam Brown will engage in a fireside chat during the event. A webcast will be accessible via their investor relations page. Health Catalyst empowers healthcare organizations with cloud-based data platforms, utilizing insights from over 100 million patient records to enhance clinical, financial, and operational outcomes, ultimately striving for data-informed healthcare decisions.

Health Catalyst (Nasdaq: HCAT) reported a 24% increase in total revenue for Q1 2021, reaching $55.846 million compared to $45.116 million in Q1 2020. Technology revenue grew 37% to $33.839 million, while professional services revenue rose 8% to $22.007 million. Despite this growth, the company experienced a 62% increase in net loss, totaling $(28.370 million). Adjusted EBITDA improved by 86% to $(837,000). Employee satisfaction remains high, with scores in the 96th percentile. The company continues to navigate challenges from the pandemic while integrating new team members.

Health Catalyst, Inc. (Nasdaq: HCAT) will report its Q1 2021 operating results on May 6, 2021, after market close. The company also plans to host a conference call at 5 p.m. E.T. to discuss these results. Participants can access the call by dialing in or through a live audio webcast available on the company's investor relations website. The replay of the conference call will be accessible for approximately 90 days. Health Catalyst provides data and analytics technology aimed at improving healthcare outcomes.